# Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

> **NCT01263327** · PHASE1 · COMPLETED · sponsor: **Xiamen University** · enrollment: 38 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **BIOLOGICAL:** HPV 16/18

## Key facts

- **NCT ID:** NCT01263327
- **Lead sponsor:** Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-07-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263327, "Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01263327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*